Patient Characteristics
| Patient no. | Clinical TNM stage | Injected dose (MBq) | No. of SNs on SPECT/CT | No. of pursued SNs | No. of groins | No. of SNs at pathology | No. of tumor-positive SNs |
| Patients evaluated with VITOM-GP | |||||||
| 1 | cT2N0Mx | 184.28 | 4 | 3 (75%) | 1 | 3 | 0 |
| 2 | cT3N0Mx | 77.87 | 2 | 1 (50%) | 1 | 5 | 0 |
| 3 | cT3N0Mx | 162.74 | 2 | 3 (100%)* | 1 | 3 | 0 |
| 4 | cT3N0Mx | 84 | 2 | 1 (50%) | 1 | 3 | 0 |
| 5 | cT2N0Mx | 83.69 | 4 | 1 (25%) | 1 | 4 | 1 |
| Total | 14 | 9 | 5 | 18 | 1 | ||
| Patients evaluated with VITOM-GC | |||||||
| 1 | cT3N0M0 | 143.23 | 3 | 2 (67%) | 1 | 3 | 1 |
| 2 | cT1N0Mx | 145.37 | 1 | 1 (100%) | 1 | 1 | 0 |
| 3 | cT1bN0Mx | 144.66 | 2 | 2 (100%) | 2 | 2 | 0 |
| 4 | cT2N0M0 | 71.62 | 2 | 2 (100%) | 2 | 4 | 0 |
| 5 | cT2N0M0 | 70.37 | 2 | 2 (100%) | 2 | 2 | 0 |
| 6 | cT1/2N0Mx | 87.51 | 5 | 1 (20%) | 1 | 7 | 0 |
| Total | 15 | 10 | 9 | 19 | 1 |
↵* Intraoperative additional SN removed.